TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Novo Nordisk Pharmatech A/S
Closing information (x1000 EUR)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
128,155
|
118,129 | |
| Earnings before taxes |
10,361
|
13,242 | |
| Total assets |
263,097
|
169,942 | |
| Current assets |
126,234
|
84,922 | |
| Current liabilities |
79,565
|
61,513 | |
| Equity capital |
177,965
|
102,901 | |
| - share capital |
1,341
|
1,342 | |
| Employees (average) |
150
|
150
|
150 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
67.6%
|
60.6% | |
| Turnover per employee |
854
|
788 | |
| Profit as a percentage of turnover |
8.1%
|
11.2% | |
| Return on assets (ROA) | |||
| Current ratio |
158.7%
|
138.1% | |
| Return on equity (ROE) |
5.8%
|
12.9% | |
| Change turnover |
10,138
|
37,856 | |
| Change turnover % |
9%
|
9%
|
47% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.